<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Minimal change disease: Treatment in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Minimal change disease: Treatment in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Minimal change disease: Treatment in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alain Meyrier, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jai Radhakrishnan, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4194236411"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Minimal change disease (MCD) is a major cause of nephrotic syndrome (approximately 90 percent) in children and in a minority of adults (approximately 10 percent). MCD and focal segmental glomerulosclerosis (FSGS) are both examples of pathogenic mechanisms that primarily affect the podocyte ("podocytopathies").</p><p>The treatment of MCD in adults will be reviewed here. Other aspects of MCD, including the diagnosis and treatment of MCD in children, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3047.html" rel="external">"Acute kidney injury (AKI) in minimal change disease and other forms of nephrotic syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p></p><p class="headingAnchor" id="H3799471521"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H4261847698"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The goal of therapy for patients with minimal change disease (MCD) is to significantly reduce proteinuria and thereby induce remission of the nephrotic syndrome. This is primarily achieved with the use of immunosuppressive agents, most commonly glucocorticoids. Although some patients may experience spontaneous remission without treatment, immunosuppressive therapy should <strong>not</strong> be withheld in an attempt to identify such patients. Such an approach exposes patients to the thrombotic and infectious hazards of persistent nephrotic syndrome and, in an older study in children, was associated with appreciable mortality from infection and thromboembolism [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1385450975"><span class="h2">Definitions of response</span><span class="headingEndMark"> — </span>The following are commonly used definitions of treatment response for adults with MCD [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete remission</strong> – A complete remission is a reduction in proteinuria to &lt;0.3 g/day or urine protein-to-creatinine ratio (UPCR) &lt;300 mg/g, stable serum creatinine, and serum albumin &gt;3.5 g/dL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial remission</strong> – A partial remission is a reduction in proteinuria of &gt;50 percent, with absolute values between 0.3 and 3.5 g/day or UPCR between 300 and 3500 mg/g. Partial remission lasting more than two weeks is an unusual event in MCD, occurring in only 2 of 51 patients in one study [<a href="#rid3">3</a>]. Furthermore, it is possible that prolonged partial remission may have focal segmental glomerulosclerosis (FSGS) that was missed on kidney biopsy, since MCD is typically an all-or-none disease [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> – A relapse is a return of proteinuria to &gt;3.5 g/day or UPCR &gt;3500 mg/g after complete remission has been achieved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequently relapsing disease</strong> – Patients are considered frequent relapsers if they have two or more relapses per six months (or four or more relapses per 12 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-dependent disease</strong> – Glucocorticoid dependence refers to relapse occurring during, or within two weeks of completing, glucocorticoid therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-resistant disease</strong> – Glucocorticoid resistance refers to the persistence of proteinuria &gt;3.5 g/day with ≤50 percent reduction from baseline after 16 weeks of adequate glucocorticoid therapy (ie, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day or 2 mg/kg every other day).</p><p></p><p class="headingAnchor" id="H3092951087"><span class="h1">INITIAL THERAPY FOR PRIMARY MCD</span></p><p class="headingAnchor" id="H1701889163"><span class="h2">Choice of initial therapy</span><span class="headingEndMark"> — </span>For most adults with primary minimal change disease (MCD), we suggest initial therapy with glucocorticoid monotherapy. For patients who cannot tolerate, have contraindications to, or do not wish to take high-dose glucocorticoids, glucocorticoid-sparing regimens are an alternative option and include calcineurin inhibitors (CNI; <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/enteric-coated mycophenolate sodium (MMF/EC-MPS) plus reduced-dose glucocorticoids. Dosing and duration of these regimens are discussed elsewhere in this topic. (See <a class="local">'Dosing and duration of preferred regimens'</a> below.)</p><p>Glucocorticoid monotherapy leads to complete remission in 80 to over 95 percent of adults with MCD [<a href="#rid3">3,5-11</a>]. The time course to a complete remission is prolonged, with 50 percent responding by four weeks and 10 to 25 percent requiring more than three to four months of therapy  (<a class="graphic graphic_figure graphicRef58623" href="/z/d/graphic/58623.html" rel="external">figure 1</a>) [<a href="#rid3">3,5,8-10</a>]. Most glucocorticoid-responsive patients will respond by 16 weeks, but some may respond as late as 21 weeks [<a href="#rid3">3</a>]. In some adults, remission may be observed during the period of tapering when a "fixed"-duration regimen of glucocorticoids is used for induction of a remission [<a href="#rid7">7</a>]. By contrast, most children will respond within four weeks [<a href="#rid12">12</a>].</p><p>The use of glucocorticoids as initial therapy is supported by several large, randomized trials in children, a single randomized trial in adults, and extensive observational studies in children and adults [<a href="#rid3">3,5-8,10,11,13-16</a>]. As noted in several large trials, almost all children (95 percent or more) with MCD respond to glucocorticoid therapy  (<a class="graphic graphic_figure graphicRef58623" href="/z/d/graphic/58623.html" rel="external">figure 1</a>) (see  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>). In a randomized trial of 31 adults published in 1970 that compared low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (&lt;30 mg/day) with no specific therapy, over 75 percent of those who received prednisone had remission of proteinuria to &lt;1 g/day within six months [<a href="#rid5">5</a>]. By comparison, only 50 percent of those in the untreated group were in remission at 18 months and approximately 70 percent were in remission at three years.</p><p>However, relapsing disease, glucocorticoid resistance, and drug-related adverse effects are common issues among adults receiving prolonged high-dose glucocorticoids as first-line therapy for MCD. For this reason, glucocorticoid-sparing immunosuppressive regimens (such as CNIs or MMF/EC-MPS) have been used to try to reduce the toxicity of long-term glucocorticoid therapy. Data from a few randomized trials and observational studies suggest that such glucocorticoid-sparing regimens appear to have similar efficacy and safety compared with glucocorticoid monotherapy and may reduce the rate of relapse [<a href="#rid6">6,17-22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial found that treatment with intravenous (IV) <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> for 10 days followed by oral <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (starting at 0.05 mg/kg/day with a target trough level of 4 to 8 ng/mL) was comparable to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg/day) at inducing complete remission over 36 weeks [<a href="#rid17">17</a>]. Rates of relapse were also similar between the groups. Similar findings were reported in another randomized trial that compared tacrolimus monotherapy (without IV methylprednisolone) with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial that randomly assigned 144 adults with MCD to receive <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (0.05 mg/kg twice daily) plus low-dose <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (0.5 mg/kg daily) or prednisolone alone (1 mg/kg daily) for up to eight weeks or until achieving complete remission, rates of complete remission at eight weeks were comparable between the groups (79 versus 77 percent, respectively) [<a href="#rid24">24</a>]. Fewer patients in the tacrolimus group experienced relapse over 24 weeks (6 versus 23 percent), and rates of adverse effects were similar between the groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter, open-label, randomized trial of 116 adults with MCD that compared EC-MPS (720 mg twice daily) plus reduced-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.5 mg/kg/day, maximum dose 40 mg daily) with conventional high-dose prednisone alone (1 mg/kg/day, maximum dose 80 mg daily), there was no significant difference between the treatment arms in the rates of complete remission after 4, 8, or 24 weeks of treatment [<a href="#rid18">18</a>]. Among patients who achieved a complete remission after four weeks of treatment, rates of relapse were comparable between the two groups. The frequency of serious adverse effects was also similar between the treatment arms.</p><p></p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> has been used as initial therapy for MCD in small case series [<a href="#rid25">25,26</a>]; however, studies comparing its efficacy with that of glucocorticoids are lacking. The use of rituximab in patients with frequently relapsing or glucocorticoid-dependent MCD is discussed elsewhere in this topic. (See <a class="local">'Rituximab'</a> below.)</p><p class="headingAnchor" id="H2754306063"><span class="h2">Dosing and duration of preferred regimens</span></p><p class="headingAnchor" id="H3124099709"><span class="h3">Glucocorticoid monotherapy</span><span class="headingEndMark"> — </span>If glucocorticoid monotherapy is used, we administer oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dose</strong> – We initiate oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a daily dose of 1 mg/kg of body weight (maximum dose 80 mg/day) [<a href="#rid2">2,6-8,10</a>]. Some clinicians prefer alternate-day prednisone at an initial dose of 2 mg/kg every other day (maximum dose of 120 mg) to minimize the toxicity of long-term daily prednisone [<a href="#rid2">2,8,11</a>]. Therapy is usually given as a single dose upon awakening (usually between 7:00 and 9:00 AM) in an attempt to minimize adrenal suppression [<a href="#rid27">27</a>]. We continue the initial dose for a minimum of four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tapering</strong> – Slow tapering is performed to sustain the remission and to avoid adrenal suppression. Shorter tapering regimens, in which glucocorticoids are tapered rapidly after remission is induced, are associated with an increased risk of relapse [<a href="#rid3">3</a>], suggesting a "rebound effect."</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who respond with complete remission, we start tapering <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> one to two weeks after complete remission is attained. Approaches to tapering prednisone vary among clinicians. One approach is to reduce the daily prednisone dose by 5 to 10 mg per week for a total period of glucocorticoid exposure of approximately 16 to 20 weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have <strong>not</strong> attained complete remission, the usual <strong>maximum duration</strong> of daily or alternate-day <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at the initial dose is 16 weeks, and patients who do not respond by this time are often considered glucocorticoid resistant. In such patients, prednisone therapy is gradually tapered to lower doses, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is preferably started along with prednisone, as described below. (See <a class="local">'Glucocorticoid-resistant MCD'</a> below.)</p><p></p><p>Data comparing one glucocorticoid regimen to another (eg, daily versus alternate-day therapy, oral regimen versus IV pulse therapy, short versus long duration) are limited. The optimal initial treatment regimen is unclear as the few randomized trials and multiple observational studies most commonly used different regimens [<a href="#rid11">11,15,28,29</a>]. One observational study comparing a shorter-duration (two months) glucocorticoid regimen with a more conventional glucocorticoid regimen in adults with MCD found similar rates of overall and frequent relapse between the groups; the cumulative glucocorticoid dose was markedly lower in the shorter-duration group [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1970477828"><span class="h3">Glucocorticoid-sparing regimens</span><span class="headingEndMark"> — </span>Glucocorticoid-sparing regimens are an alternative treatment option for patients who cannot tolerate, have contraindications to, or do not wish to take high-dose glucocorticoids. The most commonly used regimens are CNIs (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) and MMF/EC-MPS plus reduced-dose glucocorticoids. (See <a class="local">'Choice of initial therapy'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNIs</strong> – If a CNI inhibitor-based regimen is used as initial therapy, either <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is a reasonable choice.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is used, the initial dose is 3 to 5 mg/kg per day in two divided doses to maintain whole blood trough levels between 150 and 200 ng/mL [<a href="#rid2">2</a>]. If <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is used, the preferred regimen is 0.05 to 0.1 mg/kg per day in two divided doses to maintain whole blood trough levels between 4 and 7 ng/mL [<a href="#rid2">2</a>]. Once the patient has achieved complete remission, we continue these doses for an additional 12 weeks, then gradually taper the dose over eight weeks to discontinuation. The total duration of treatment is approximately six months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have contraindications to or who do not wish to receive glucocorticoids, CNIs can be administered as monotherapy [<a href="#rid23">23</a>]. In the absence of contraindications, some clinicians administer the CNI with reduced-dose glucocorticoids, such as <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.3 mg/kg per day (maximum dose 30 mg/day) [<a href="#rid24">24</a>], although the addition of glucocorticoids to a CNI is not necessary. Once the patient has achieved complete remission, the prednisone is tapered over four to six weeks to discontinuation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MMF/EC-MPS plus reduced-dose glucocorticoids</strong> – If a mycophenolate-based regimen is used as initial therapy, either MMF or EC-MPS is a reasonable choice.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If MMF is used, we give 0.5 g twice daily for the first week, then 1 g twice daily thereafter. If EC-MPS is used, we give 360 mg twice daily for the first week, then 720 mg twice daily thereafter. We usually continue these doses for a total of six months and then discontinue the drug [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MMF/EC-MPS should be administered with reduced-dose glucocorticoids [<a href="#rid18">18</a>]. We give <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day (maximum dose 40 mg/day). Once the patient has achieved complete remission, we taper the prednisone over four to six weeks to discontinuation. Some experts choose to taper the prednisone more gradually over four to five months [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H4109747905"><span class="h2">Supportive measures in all patients</span><span class="headingEndMark"> — </span>General supportive measures in all patients with MCD include dietary sodium restriction, blood pressure control, and in selected patients, anticoagulation. Dietary protein restriction, renin-angiotensin system inhibition to treat proteinuria, and statin therapy to treat dyslipidemia are not usually needed in patients with MCD, except in those with glucocorticoid resistance and nephrotic syndrome persisting for several months. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition [<a href="#rid31">31</a>]. This approach is consistent with the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases [<a href="#rid2">2</a>]. These issues are discussed in greater detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary sodium and protein restriction (see  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Salt intake'</a> and  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Protein intake'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antihypertensive therapy (see  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renin-angiotensin system inhibition (see  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Renin-angiotensin system inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipid lowering (see  <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome", section on 'Management'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation (see  <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Patients with other causes of nephrotic syndrome'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of edema (see  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Volume overload'</a>)</p><p></p><p class="headingAnchor" id="H852615122"><span class="h2">Monitoring the response to therapy</span><span class="headingEndMark"> — </span>All patients who are receiving treatment for primary MCD should be closely monitored for clinical response to therapy. We perform a clinical assessment and monitor a spot urine protein-to-creatinine ratio, serum albumin, and serum creatinine on a monthly basis. Remissions are typically abrupt, with the patient being free of proteinuria within two to three weeks from the time of initial response. In a majority of cases, response to therapy of nephrotic MCD is of an "all or nothing" type. Partial responses are not characteristic of MCD and, when seen, one should suspect a possible misdiagnosis, most often focal segmental glomerulosclerosis (FSGS) that was missed by sampling error. (See <a class="local">'Definitions of response'</a> above.)</p><p class="headingAnchor" id="H1916656178"><span class="h1">RELAPSING DISEASE</span><span class="headingEndMark"> — </span>Disease relapse is defined as a return of proteinuria to &gt;3.5 g/day in patients who had previously undergone a complete remission. This is usually followed by a decrease in the serum albumin concentration from its previous baseline. Approximately 50 to 75 percent of glucocorticoid-responsive adults will have a relapse, and frequent relapses occur in 10 to 25 percent [<a href="#rid3">3,8,10,32</a>]. Glucocorticoid dependence is seen in 25 to 30 percent [<a href="#rid3">3,10</a>]. (See <a class="local">'Definitions of response'</a> above.)</p><p>Most relapses occur within one year after glucocorticoid therapy has been tapered or discontinued, although occasional patients have a glucocorticoid-responsive relapse after as long as 25 years in remission [<a href="#rid6">6,8,33,34</a>]. Relapses may be triggered by allergies or infections, especially viral infections [<a href="#rid3">3</a>]. In such cases, the relapse can last for a limited period and may respond to a shorter treatment duration than initial therapy, often within one month. Cases of relapse following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have also been reported [<a href="#rid35">35-37</a>]. (See  <a class="medical medical_review" href="/z/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'COVID-19 vaccine-associated glomerular disease'</a>.)</p><p class="headingAnchor" id="H3976382633"><span class="h2">Monitoring for relapse</span><span class="headingEndMark"> — </span>Patients who relapse require reinstitution of therapy, and early detection is beneficial. Once patients have achieved complete remission, we ask them to test their urine with a dipstick for protein every one to two weeks for at least the first six months to monitor for disease relapse. A positive test should be repeated the next day and, if still positive, the clinician should be contacted. Most cases of relapse have an abrupt onset, and patients often will self-diagnose relapse when they observe the passage of foamy urine [<a href="#rid38">38</a>] or sudden onset of edema.</p><p class="headingAnchor" id="H2166896220"><span class="h2">Infrequent relapse</span><span class="headingEndMark"> — </span>For most patients with infrequent relapses (fewer than four per year), we suggest a repeat course of the initial therapy used to achieve complete remission, rather than switching therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>If the patient received glucocorticoid monotherapy as initial therapy, we usually administer a repeat course of glucocorticoids. An exception is in patients who have previously developed significant adverse effects related to initial therapy with glucocorticoids; in such patients, switching to a glucocorticoid-sparing regimen may be preferred (see <a class="local">'Glucocorticoid-sparing regimens'</a> above). The optimal dose and duration of glucocorticoids for infrequent relapse is uncertain. We prefer to give a shorter course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to minimize overall glucocorticoid exposure, particularly if the relapse has occurred after a relatively long period off prednisone or when it is caused by an intercurrent benign viral or allergic event. We administer oral prednisone at a daily dose of 1 mg/kg (maximum dose of 80 mg per day) for four weeks; if remission is attained, the dose is then tapered in 5 mg decrements every three to five days to discontinuation within one to two months. Some nephrologists choose to repeat the initial prednisone regimen rather than to give a shorter course.</p><p></p><p class="bulletIndent1">Subsequent relapses, if not frequent, can also be treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> if significant side effects have not developed. A longer course of prednisone (as administered for initial therapy) can be used in patients who relapse during the taper of a short course of glucocorticoids or within four months of completing the short course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient received a glucocorticoid-sparing regimen (eg, a calcineurin inhibitor [CNI] or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/enteric-coated mycophenolate sodium [MMF/EC-MPS] plus reduced-dose glucocorticoids) as initial therapy, we administer the same regimen that was used to achieve complete remission. (See <a class="local">'Glucocorticoid-sparing regimens'</a> above.)</p><p></p><p>There is no high-quality evidence to guide the optimal therapy of infrequent relapse. In observational studies of patients who were able to taper off <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> after achieving complete remission, a repeat, shorter course of prednisone often resulted in a prompt clinical remission [<a href="#rid6">6-8</a>]. One small, randomized trial that compared <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> combined with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (0.8 mg/kg/day) versus prednisolone alone (1 mg/kg/day) in 52 adults with a first relapse of minimal change disease (MCD) found a shorter time to remission in the cyclosporine group; however, there was no significant difference between the groups in rates of complete remission at six months [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H62834667"><span class="h2">Frequently relapsing or glucocorticoid-dependent MCD</span><span class="headingEndMark"> — </span>There are a variety of therapeutic approaches in patients who have frequent relapses (defined as two or more relapses per six months, or four or more relapses per 12 months) or who are glucocorticoid dependent (relapse occurring during, or within two weeks of completing, glucocorticoid therapy). (See <a class="local">'Definitions of response'</a> above.)</p><p class="headingAnchor" id="H2525811610"><span class="h3">General approach</span><span class="headingEndMark"> — </span>For patients with frequently relapsing or glucocorticoid-dependent (FR/GD) MCD, we recommend treatment with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, a CNI (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), or MMF/EC-MPS, rather than glucocorticoid monotherapy.</p><p>The choice among these regimens depends upon several factors, including clinician and patient preference, drug availability and cost, efficacy, toxicity, and tolerability. There is limited evidence directly comparing one drug class with another in the treatment of patients with FR/GD MCD, and available data have not established that one regimen is superior to another. Most of the contributors to this topic prefer <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> for most patients, particularly those who have previously received a CNI or MMF/EC-MPS as part of a glucocorticoid-sparing regimen, based upon low-quality evidence showing more durable remissions with these agents compared with a CNI. However, any of these drug classes are preferred over glucocorticoids to avoid the morbidity associated with prolonged glucocorticoid exposure.</p><p>In general, patients with FR/GD MCD who are in relapse should be retreated with glucocorticoids (or a glucocorticoid-sparing regimen) until remission is attained before a second-line therapy is initiated. Following initiation of the second-line therapy, glucocorticoids (or a glucocorticoid-sparing regimen) are gradually tapered to discontinuation over one month, if possible. If the patient continues to be dependent on glucocorticoids after three to six months of treatment, then the second-line therapy should be discontinued and an alternative regimen should be considered.</p><p>Patients receiving treatment for FR/GD MCD should be monitored using the same approach as those receiving initial therapy for MCD. (See <a class="local">'Monitoring the response to therapy'</a> above.)</p><p>Data from observational studies and a few small, randomized, controlled trials suggest that <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, CNIs, and MMF/EC-MPS reduce the rate of relapse and induce remission in approximately 70 to 90 percent of adults with FR/GD MCD [<a href="#rid3">3,6,11,39-46</a>]. The dosing and efficacy of specific immunosuppressive regimens used for FR/GD MCD are discussed below.</p><p class="headingAnchor" id="H4026808638"><span class="h3">Dosing and efficacy</span></p><p class="headingAnchor" id="H3716214724"><span class="h4">Cyclophosphamide</span><span class="headingEndMark"> — </span>The hazards of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> therapy, especially that of infertility, must be clearly explained to the patient and/or guardians for ethical and legal reasons before beginning this treatment. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases", section on 'Gonadal toxicity'</a>.)</p><p>If <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is used for patients with FR/GD MCD, we administer oral cyclophosphamide at a dose of 2 mg/kg per day (maximum daily dose 200 mg) for 12 weeks. Data in adults and children indicate that an eight-week course may be less effective [<a href="#rid3">3,6,47</a>]. The dose of cyclophosphamide is reduced as needed to maintain a white blood cell count &gt;3500 cells/microL and an absolute neutrophil count (ANC) of &gt;1500 cells/microL. (See  <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Daily oral cyclophosphamide'</a>.)</p><p>Given the side effects of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, prolonged therapy (&gt;12 weeks) and repeated courses must be <strong>avoided</strong>. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>.)</p><p>Evidence for the efficacy of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> in adults with FR/GD MCD comes primarily from one randomized trial and several observational studies, which collectively show that cyclophosphamide induces remission in approximately 75 percent of such patients [<a href="#rid1">1,3,6,10,11,14,44</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 14 patients, treatment with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2 mg/kg per day for eight weeks) resulted in complete, relapse-free remission in four of five FR patients and four of nine GD patients [<a href="#rid3">3</a>]. The remaining five GD patients were able to be weaned off glucocorticoids but had subsequent relapses. At final follow-up, 11 were in complete remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 66 children and adults, 11 adults with FR/GD MCD were randomly assigned to <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (2.5 mg/kg for eight weeks) or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (5 mg/kg per day for nine months, then tapered off by month 12) [<a href="#rid44">44</a>]. All of the adults achieved remission; three patients in each group eventually relapsed, occurring in the first year following therapy with cyclophosphamide and earlier after discontinuation of cyclosporine. Among children, the rate of stable disease at two years was significantly higher with cyclophosphamide (68 versus 20 percent). There were too few adults for a meaningful comparison, although other studies have also found a high rate of relapse following cessation of cyclosporine.</p><p></p><p class="headingAnchor" id="H2478093532"><span class="h4">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is an anti-CD20 monoclonal antibody that depletes CD20-positive cells. If rituximab is used for patients with FR/GD MCD, we typically administer rituximab as 1 g initially followed 14 days later by another 1 g dose. Other clinicians may use an alternative regimen, administering 375 mg/m<sup>2</sup> weekly for four weeks or a B cell count–driven approach in which a second dose of 375 mg/m<sup>2</sup> is given if ≥5 circulating B cells/microL are detected by flow cytometry one week after treatment.</p><p>In patients with FR/GD MCD who respond to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, some experts choose to administer maintenance rituximab to prevent relapse. There are no data to guide this approach; some contributors to this topic would give rituximab 1 g every six months for two to three years and then discontinue maintenance therapy.</p><p>Observational studies suggest that <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be effective therapy in adults with FR/GD MCD [<a href="#rid42">42,43,48-50</a>]. In a systematic review and meta-analysis of 21 studies involving 382 adults with FR/GD MCD or focal segmental glomerulosclerosis (FSGS), rituximab therapy induced complete remission in 92 percent of those with MCD, although 28 percent of the patients relapsed during follow-up [<a href="#rid50">50</a>]. Rituximab was well tolerated and associated with few adverse events. </p><p>Other anti-CD20 monoclonal antibodies such as <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">obinutuzumab</a> have been evaluated for the treatment of FR/GD nephrotic syndrome in children, including disease resistant to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid51">51</a>], but have not yet been studied in adults with FR/GD MCD. </p><p>Data pertaining to the use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in children with MCD are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Rituximab'</a>.)</p><p class="headingAnchor" id="H1959061572"><span class="h4">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>If <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is used for patients with FR/GD MCD, the initial dose is 3 to 5 mg/kg per day in two divided doses to maintain whole blood trough levels between 150 and 200 ng/mL. If <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is used, the initial dose is 0.05 to 0.1 mg/kg per day in two divided doses to maintain whole blood trough levels between 4 and 7 ng/mL.</p><p>The optimal duration of therapy in patients who respond is not known, but prolonged therapy is given to minimize the risk of relapse. We treat with the initial dose of CNI for at least 12 to 18 months, then taper to the smallest dose that maintains a remission and avoids nephrotoxicity (preferably less than 3 mg/kg per day of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or less than 0.05 mg/kg per day of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>). This dose is maintained for 18 to 24 months, then slowly tapered to discontinuation over four to six months.</p><p>Numerous observational studies and a small, randomized trial suggest that approximately 70 and 90 percent of GD or FR patients, respectively, will undergo complete or partial remission when treated with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid13">13,44,52-55</a>]. Similar results have been reported with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid23">23,56-59</a>]. Over 60 percent of FR/GD patients who respond to cyclosporine will relapse (usually within six months) after cyclosporine is discontinued if the duration of therapy is relatively short [<a href="#rid44">44,52,60</a>]. A sustained remission is more likely if patients are maintained on cyclosporine for one year or longer, with therapy then slowly tapered to discontinuation [<a href="#rid52">52,53</a>].</p><p>Although <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is potentially nephrotoxic, it appears that prolonged therapy with lower doses of cyclosporine can maintain remission without nephrotoxicity. In one study, for example, patients who went into remission showed no signs of cyclosporine nephrotoxicity on repeat biopsy at a mean of 20 months as long as the daily dose of cyclosporine (non-microemulsion preparation) was below 5.5 mg/kg per day [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H119729116"><span class="h4">Mycophenolate mofetil/sodium</span><span class="headingEndMark"> — </span>If MMF is used for patients with FR/GD MCD, we give 0.5 g twice daily for the first week, then 1 g twice daily thereafter. If EC-MPS is used, we give 360 mg twice daily for the first week, then 720 mg twice daily thereafter. We usually continue these doses of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> for at least one year and then attempt to gradually taper the drug to discontinuation, if possible.</p><p>Data on the use of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> in patients with FR/GD MCD are limited but suggest some benefit [<a href="#rid11">11,46,61-63</a>]. As an example, in an observational study that included 18 adults with FR/GD MCD who received MMF (2000 mg/day) or EC-MPS (1440 mg/day) plus low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (10 mg/day), 16 (89 percent) achieved complete remission, one achieved partial remission, and one was resistant to MMF [<a href="#rid46">46</a>]. Among the 11 who completed the first cycle of MMF/EC-MPS, seven (64 percent) maintained remission after a mean of 33 months.</p><p class="headingAnchor" id="H386458347"><span class="h1">GLUCOCORTICOID-RESISTANT MCD</span><span class="headingEndMark"> — </span>Glucocorticoid resistance refers to the persistence of proteinuria &gt;3.5 g/day with ≤50 percent reduction from baseline after 16 weeks of adequate glucocorticoid therapy (ie, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg/day or 2 mg/kg every other day). Approximately 5 to 10 percent of adults with minimal change disease (MCD) appear to be glucocorticoid resistant. However, some experts would argue that glucocorticoid-resistant MCD actually reflects an early stage of focal segmental glomerulosclerosis (FSGS) or unsampled primary FSGS. (See <a class="local">'Definitions of response'</a> above.)</p><p class="headingAnchor" id="H405038052"><span class="h2">Causes of glucocorticoid resistance</span><span class="headingEndMark"> — </span>Glucocorticoid resistance is most often due to one of the following problems:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate initial glucocorticoid therapy</strong> – Inadequate initial glucocorticoid therapy due to treatment nonadherence or treatment for less than 16 weeks may be a cause of apparent glucocorticoid resistance. In addition, in some patients treated with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (rather than with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>), the use of prescribed or over-the-counter aluminum-containing antacids can decrease the bioavailability of the glucocorticoid. A longer course of daily therapy induces remission in some of these cases. In children who do not respond by four weeks, a failure to respond to a trial of pulse <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> is considered indicative of glucocorticoid resistance. Some nephrologists apply this approach (eg, methylprednisolone 0.5 to 1 g every other day for three doses) to define glucocorticoid resistance in adults who do not have some response to oral glucocorticoids by 8 to 12 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incorrect diagnosis</strong> – Another common cause for apparent glucocorticoid resistance is an incorrect diagnosis, most often FSGS (either of the primary, secondary, or genetic form) that is missed by sampling error or inadequate examination of the kidney biopsy, particularly if the kidney biopsy comprises few glomeruli and only superficial cortical tufts. As mentioned previously, remissions of MCD are typically abrupt, with the patient being free of proteinuria within two to three weeks from the time of initial response. Partial responses are not characteristic of MCD [<a href="#rid7">7</a>], and when seen, one should suspect a possible misdiagnosis, most often FSGS.</p><p></p><p class="bulletIndent1">The first step is to reevaluate the original kidney biopsy since segmental sclerosis in one glomerulus is sufficient to establish the diagnosis of FSGS. Most experts, including the authors of this topic, would repeat the kidney biopsy if reevaluation of the original specimen is unrevealing, or if the initial biopsy did not include electron microscopy, and glucocorticoid unresponsiveness is present. (See <a class="local">'Role of repeat kidney biopsy'</a> below and  <a class="medical medical_review" href="/z/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Distinguishing MCD from primary FSGS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimal change variants</strong> – Glucocorticoid resistance may also be seen in one of the variants of idiopathic nephrotic syndrome other than FSGS, such as idiopathic mesangial proliferation, immunoglobulin M (IgM) nephropathy, or C1q nephropathy. (See  <a class="medical medical_review" href="/z/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Minimal change variants'</a>.)</p><p></p><p class="headingAnchor" id="H12964569"><span class="h2">Role of repeat kidney biopsy</span><span class="headingEndMark"> — </span>The value of repeat kidney biopsy in patients with glucocorticoid-resistant MCD is unclear. Histologic examination will show either FSGS or MCD. However, if MCD is again seen, one cannot exclude underlying FSGS that was missed by sampling error. Furthermore, the findings on repeat biopsy do not affect therapy, since the treatment of choice is <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for both glucocorticoid-resistant MCD and glucocorticoid-resistant FSGS [<a href="#rid3">3</a>].</p><p>On the other hand, some experts (including the authors) consider the finding of FSGS of repeat biopsy to be valuable in glucocorticoid-resistant patients since it identifies a patient with a worse long-term prognosis, even though it does not modify the choice of management over the short term. Repeat kidney biopsy is indicated in patients treated with a calcineurin inhibitor (CNI) in whom serum creatinine rises by &gt;30 percent over baseline to assess for treatment-induced vascular and interstitial lesions [<a href="#rid53">53</a>] or alternatively to diagnose progression to lesions of FSGS.</p><p>Data pertaining to repeat kidney biopsy in patients with MCD are limited. In a review of 25 children with MCD who underwent repeat biopsy, most often prior to a change in therapy, four had MCD and 21 had FSGS or IgM nephropathy [<a href="#rid64">64</a>]. The distribution was different in a series of 35 adults with MCD on initial biopsy: Repeat biopsy showed MCD in 22 and FSGS in 13 [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H2720847072"><span class="h2">Treatment of glucocorticoid-resistant MCD</span><span class="headingEndMark"> — </span>The optimal therapeutic approach to patients with glucocorticoid-resistant MCD is not known. In general, we treat these patients with a CNI (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) with or without low-dose glucocorticoids, using the same approach as that used for patients with glucocorticoid-resistant FSGS. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Glucocorticoid-dependent or glucocorticoid-resistant disease'</a>.)</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> has documented efficacy in glucocorticoid-resistant MCD, although long-term results are less well defined [<a href="#rid11">11,40,52,65,66</a>]. The following observations illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial evaluated the efficacy of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in 13 adults and children with glucocorticoid-resistant MCD compared with supportive care [<a href="#rid10">10</a>]. The cyclosporine dose was 5 mg/kg per day for six months, which was then tapered by 25 percent every two months until discontinuation. Complete or partial remission was induced in five of eight treated adults without significant nephrotoxicity or other side effects. Positive responses occurred within two months after the onset of therapy, while lack of antiproteinuric effect at three months was generally indicative of resistance to cyclosporine. Despite the initial benefit, relapses were common after cessation of therapy, and mean urinary protein excretion at the end of the study was not different between treated and control groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a report from France that combined two prospective, uncontrolled trials, 21 adults with glucocorticoid-resistant MCD were treated with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (5 mg/kg per day in two divided doses) with or without <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (10 to 15 mg/day) [<a href="#rid40">40</a>]. Fourteen patients were in complete or partial remission at six months, but many had recurrence of proteinuria upon cyclosporine taper. Responses were more likely among those concurrently receiving prednisone.</p><p></p><p class="headingAnchor" id="H2133745815"><span class="h1">SIDE EFFECTS OF IMMUNOSUPPRESSIVE THERAPY</span><span class="headingEndMark"> — </span>The immunosuppressive agents used to treat minimal change disease (MCD) are associated with significant side effects. These toxicities are described in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids (see  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (see  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> (see  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> (see  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> (see  <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a>)</p><p></p><p>The long-term complications of cytotoxic therapies may be less common in MCD since relatively short courses are used. However, the toxicity of these agents must be considered in treating patients with MCD, particularly since progressive kidney failure is rare in the absence of progression to focal segmental glomerulosclerosis (FSGS) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2273585311"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2748525549"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>The optimal approach to the treatment of primary minimal change disease (MCD) in pregnant patients is not known. Most contributors of this topic would treat with immunosuppressive therapy, preferably with glucocorticoids. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> may also be used but appear to be less safe. Cyclosporine may be associated with increased rates of premature birth and low birth weight [<a href="#rid67">67</a>]. Similarly, infants exposed to tacrolimus in utero are at risk of premature birth, birth defects, low birth weight, and fetal distress. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/enteric-coated mycophenolate sodium (MMF/EC-MPS) should be <strong>avoided</strong> in pregnant patients. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>We suggest that pregnant patients with MCD be referred to centers with expertise in the management of glomerular disease in pregnancy. Pregnant patients with kidney disease should be jointly managed by a nephrologist and by a maternal-fetal medicine specialist. (See  <a class="medical medical_review" href="/z/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease", section on 'Management during pregnancy'</a>.)</p><p>A detailed discussion of pregnancy in patients with underlying kidney disease and the general management of nephrotic syndrome in pregnancy are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome", section on 'Management of nephrotic syndrome in pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H4059339773"><span class="h2">Patients with MCD and AKI</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) can occur in patients with MCD, and sometimes, the glomerular filtration rate does not fully recover to baseline. Some patients do not recover sufficient kidney function to allow withdrawal from dialysis, despite confirmed MCD on a repeat kidney biopsy [<a href="#rid68">68</a>]. This complication and its management are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3047.html" rel="external">"Acute kidney injury (AKI) in minimal change disease and other forms of nephrotic syndrome"</a>.)</p><p class="headingAnchor" id="H2823454127"><span class="h2">Patients with secondary causes of MCD</span><span class="headingEndMark"> — </span>Secondary MCD has been attributed to a variety of agents and conditions. In general, the treatment of secondary MCD focuses on cessation of the offending drug or effective treatment of the underlying disease, which is usually associated with improvement in the nephrotic syndrome. Among patients with MCD associated with malignancy, the decision to treat with glucocorticoids or other immunosuppressive agents should be jointly taken by the nephrologist and the oncologist. (See  <a class="medical medical_review" href="/z/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Etiology'</a>.)</p><p>MCD is a cause of the nephrotic syndrome that occurs following hematopoietic cell transplantation (HCT). The treatment of MCD after HCT is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Minimal change disease'</a>.)</p><p class="headingAnchor" id="H1733891942"><span class="h2">MCD after kidney transplantation</span><span class="headingEndMark"> — </span>De novo and recurrent MCD are rare after kidney transplantation [<a href="#rid69">69,70</a>]. The development of recurrent nephrotic syndrome in a transplant recipient with MCD as the cause of end-stage kidney disease (ESKD) should raise concern for the possibility of recurrent primary focal segmental glomerulosclerosis (FSGS) that was originally misdiagnosed in the native kidneys as MCD. (See  <a class="medical medical_review" href="/z/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney"</a>.)</p><p class="headingAnchor" id="H315848854"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The outcome of treated minimal change disease (MCD) is favorable, with the great majority of patients eventually attaining complete remission [<a href="#rid71">71-73</a>]. The most important prognostic factor appears to be the initial response to glucocorticoid therapy. Without treatment, the rate of spontaneous early remission (eg, within a few months) in adults is approximately 5 to 10 percent [<a href="#rid5">5,8,10</a>]. A substantial proportion of untreated patients eventually undergo remission after a prolonged period [<a href="#rid3">3,5</a>]. In a series of 51 patients, for example, 33 percent had a spontaneous remission at some time during the disease course [<a href="#rid3">3</a>]. However, during the period between disease onset and spontaneous remission (which may take years), untreated patients are exposed to the risks of severe nephrotic syndrome, including thromboembolic events, acute kidney injury (AKI), and infection.</p><p>Although many patients with MCD have a modest decrease in the glomerular filtration rate during the nephrotic phase, this may represent "functional kidney impairment," as kidney function returns to normal following resolution of the nephrotic syndrome, even after multiple relapses [<a href="#rid3">3,6-8,10</a>]. In a series of 51 patients, 61 percent had higher-than-normal serum creatinine values when patients were actively nephrotic, but kidney function returned to normal when remission was achieved [<a href="#rid3">3</a>]. In adults, the nephrotic syndrome may also be associated with a rise in blood pressure over prenephrotic baseline levels [<a href="#rid3">3</a>].</p><p>End-stage kidney disease (ESKD) is rare and has mostly been reported in glucocorticoid-resistant cases [<a href="#rid8">8,72</a>], including those with persistent AKI [<a href="#rid68">68</a>]. However, focal segmental glomerulosclerosis (FSGS) is often seen on a late kidney biopsy in patients with glucocorticoid-resistant disease and in all patients who develop progressive kidney failure. Whether this represents sampling error on the initial kidney biopsy due to the focal nature of FSGS, or true progression from MCD to FSGS, is uncertain. (See  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H2398628273"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H3027738974"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The goal of therapy for patients with minimal change disease (MCD) is to significantly reduce proteinuria and thereby induce remission of the nephrotic syndrome. This is primarily achieved with the use of immunosuppressive agents, most commonly glucocorticoids. Untreated MCD is associated with potentially fatal complications, including sepsis and thrombosis. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy for primary MCD</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most adults with primary MCD, we suggest initial therapy with glucocorticoid monotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Glucocorticoid monotherapy leads to complete remission in 80 to over 95 percent of adults with MCD. For patients who cannot tolerate, have contraindications to, or do not wish to take high-dose glucocorticoids, glucocorticoid-sparing regimens are an alternative option and include calcineurin inhibitors (CNIs; <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/enteric-coated mycophenolate sodium (MMF/EC-MPS) plus reduced-dose glucocorticoids. Dosing and duration of these regimens are discussed above. (See <a class="local">'Choice of initial therapy'</a> above and <a class="local">'Dosing and duration of preferred regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>General supportive measures in all patients with MCD include dietary sodium restriction, blood pressure control, and in select patients, anticoagulation. Dietary protein restriction, renin-angiotensin system inhibition to treat proteinuria, and statin therapy to treat dyslipidemia are not usually needed, except in patients with glucocorticoid resistance. (See <a class="local">'Supportive measures in all patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients should be closely monitored for clinical response to therapy. We perform a clinical assessment and monitor a spot urine protein-to-creatinine ratio, serum albumin, and serum creatinine on a monthly basis. Remissions are typically abrupt, with the patient being free of proteinuria within two to three weeks from the time of initial response. Partial responses are not characteristic of MCD, and when seen, one should suspect a possible misdiagnosis, most often FSGS that was missed by sampling error. (See <a class="local">'Monitoring the response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing disease</strong> – Approximately 50 to 75 percent of adults will have a relapse, and frequent relapses (FR) occur in 10 to 25 percent. Glucocorticoid dependence is seen in 25 to 30 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infrequent relapse</strong> – For most patients with infrequent relapses (fewer than four per year), we suggest a repeat course of the initial therapy used to achieve complete remission, rather than switching therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). An exception is in patients who have previously developed significant adverse effects related to initial therapy with glucocorticoids; in such patients, switching to a glucocorticoid-sparing regimen may be preferred. (See <a class="local">'Infrequent relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frequently relapsing or glucocorticoid-dependent (FR/GD) MCD</strong> – For patients with FR/GD MCD, we recommend treatment with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, a CNI (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), or MMF/EC-MPS, rather than glucocorticoid monotherapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The choice among these regimens depends upon several factors, including clinician and patient preference, drug availability and cost, efficacy, toxicity, and tolerability. Most of the contributors to this topic prefer cyclophosphamide or rituximab for most patients, particularly those who have previously received a CNI or MMF/EC-MPS as part of a glucocorticoid-sparing regimen, based upon low-quality evidence showing more durable remissions with these agents compared with a CNI. However, any of these drug classes are preferred over glucocorticoids to avoid the morbidity associated with prolonged glucocorticoid exposure. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-resistant MCD</strong> – The optimal therapeutic approach to patients with glucocorticoid-resistant MCD is not known. Some experts argue that glucocorticoid-resistant MCD actually reflects an early stage of focal segmental glomerulosclerosis (FSGS) or unsampled primary FSGS. In general, we treat these patients with a CNI (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) with or without low-dose glucocorticoids, using the same approach as that used for patients with glucocorticoid-resistant FSGS. This is discussed in more detail elsewhere. (See <a class="local">'Treatment of glucocorticoid-resistant MCD'</a> above and  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Glucocorticoid-dependent or glucocorticoid-resistant disease'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arneil GC, Lam CN. Long-term assessment of steroid therapy in childhood nephrosis. Lancet 1966; 2:819.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1.</a></li><li><a class="nounderline abstract_t">Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 1996; 11:2192.</a></li><li><a class="nounderline abstract_t">Ahmad H, Tejani A. Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron 2000; 84:342.</a></li><li><a class="nounderline abstract_t">Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970; 3:421.</a></li><li><a class="nounderline abstract_t">Nolasco F, Cameron JS, Heywood EF, et al. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 1986; 29:1215.</a></li><li><a class="nounderline abstract_t">Fujimoto S, Yamamoto Y, Hisanaga S, et al. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis 1991; 17:687.</a></li><li><a class="nounderline abstract_t">Nakayama M, Katafuchi R, Yanase T, et al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39:503.</a></li><li><a class="nounderline abstract_t">Korbet SM, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol 1988; 8:291.</a></li><li><a class="nounderline abstract_t">Tse KC, Lam MF, Yip PS, et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 2003; 18:1316.</a></li><li><a class="nounderline abstract_t">Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2:445.</a></li><li><a class="nounderline abstract_t">The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98:561.</a></li><li><a class="nounderline abstract_t">Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. J Am Soc Nephrol 2013; 24:702.</a></li><li><a class="nounderline abstract_t">Huang JJ, Hsu SC, Chen FF, et al. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am J Nephrol 2001; 21:28.</a></li><li><a class="nounderline abstract_t">Nair RB, Date A, Kirubakaran MG, Shastry JC. Minimal-change nephrotic syndrome in adults treated with alternate-day steroids. Nephron 1987; 47:209.</a></li><li><a class="nounderline abstract_t">Wang F, Looi LM, Chua CT. Minimal change glomerular disease in Malaysian adults and use of alternate day steroid therapy. Q J Med 1982; 51:312.</a></li><li><a class="nounderline abstract_t">Li X, Liu Z, Wang L, et al. Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome. J Am Soc Nephrol 2017; 28:1286.</a></li><li><a class="nounderline abstract_t">Rémy P, Audard V, Natella PA, et al. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney Int 2018; 94:1217.</a></li><li><a class="nounderline abstract_t">Matsumoto H, Nakao T, Okada T, et al. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Intern Med 2004; 43:668.</a></li><li><a class="nounderline abstract_t">Al-Khader AA, Lien JW, Aber GM. Cyclophosphamide alone in the treatment of adult patients with minimal change glomerulonephritis. Clin Nephrol 1979; 11:26.</a></li><li><a class="nounderline abstract_t">Cameron JS, Turner DR, Ogg CS, et al. The nephrotic syndrome in adults with 'minimal change' glomerular lesions. Q J Med 1974; 43:461.</a></li><li><a class="nounderline abstract_t">Uldall PR, Feest TG, Morley AR, et al. Cyclophosphamide therapy in adults with minimal-change nephrotic syndrome. Lancet 1972; 1:1250.</a></li><li><a class="nounderline abstract_t">Medjeral-Thomas NR, Lawrence C, Condon M, et al. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial. Clin J Am Soc Nephrol 2020; 15:209.</a></li><li><a class="nounderline abstract_t">Chin HJ, Chae DW, Kim YC, et al. Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults. J Am Soc Nephrol 2021; 32:199.</a></li><li><a class="nounderline abstract_t">Guan N, Zhang M, Zhang M, et al. Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease. Kidney Int Rep 2023; 8:1102.</a></li><li><a class="nounderline abstract_t">Fenoglio R, Sciascia S, Beltrame G, et al. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget 2018; 9:28799.</a></li><li><a class="nounderline abstract_t">Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA 1999; 282:671.</a></li><li><a class="nounderline abstract_t">Imbasciati E, Gusmano R, Edefonti A, et al. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br Med J (Clin Res Ed) 1985; 291:1305.</a></li><li><a class="nounderline abstract_t">Yeung CK, Wong KL, Ng WL. Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome. Aust N Z J Med 1983; 13:349.</a></li><li><a class="nounderline abstract_t">Ozeki T, Katsuno T, Hayashi H, et al. Short-Term Steroid Regimen for Adult Steroid-Sensitive Minimal Change Disease. Am J Nephrol 2019; 49:54.</a></li><li><a class="nounderline abstract_t">Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:268.</a></li><li><a class="nounderline abstract_t">Lionaki S, Mantios E, Tsoumbou I, et al. Clinical Characteristics and Outcomes of Adults with Nephrotic Syndrome Due to Minimal Change Disease. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Coggins CH. Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. Trans Am Clin Climatol Assoc 1986; 97:18.</a></li><li><a class="nounderline abstract_t">Pru C, Kjellstrand CM, Cohn RA, Vernier RL. Late recurrence of minimal lesion nephrotic syndrome. Ann Intern Med 1984; 100:69.</a></li><li><a class="nounderline abstract_t">Komaba H, Wada T, Fukagawa M. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78:469.</a></li><li><a class="nounderline abstract_t">Kervella D, Jacquemont L, Chapelet-Debout A, et al. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine. Kidney Int 2021; 100:457.</a></li><li><a class="nounderline abstract_t">Schwotzer N, Kissling S, Fakhouri F. Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine". Kidney Int 2021; 100:458.</a></li><li><a class="nounderline abstract_t">Khitan ZJ, Glassock RJ. Foamy Urine: Is This a Sign of Kidney Disease? Clin J Am Soc Nephrol 2019; 14:1664.</a></li><li><a class="nounderline abstract_t">Eguchi A, Takei T, Yoshida T, et al. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant 2010; 25:124.</a></li><li><a class="nounderline abstract_t">Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991; 35 Suppl 1:S37.</a></li><li><a class="nounderline abstract_t">Lee HY, Kim HS, Kang CM, et al. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea. Clin Nephrol 1995; 43:375.</a></li><li><a class="nounderline abstract_t">Iwabuchi Y, Takei T, Moriyama T, et al. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore) 2014; 93:e300.</a></li><li><a class="nounderline abstract_t">Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83:511.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993; 8:1326.</a></li><li><a class="nounderline abstract_t">Guitard J, Hebral AL, Fakhouri F, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant 2014; 29:2084.</a></li><li><a class="nounderline abstract_t">Sandoval D, Poveda R, Draibe J, et al. Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. Clin Kidney J 2017; 10:632.</a></li><li><a class="nounderline abstract_t">Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987; 62:1102.</a></li><li><a class="nounderline abstract_t">Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011; 76:151.</a></li><li><a class="nounderline abstract_t">Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol 2013; 9:154.</a></li><li><a class="nounderline abstract_t">Xue C, Yang B, Xu J, et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clin Kidney J 2021; 14:1042.</a></li><li><a class="nounderline abstract_t">Dossier C, Bonneric S, Baudouin V, et al. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children. Clin J Am Soc Nephrol 2023; 18:1555.</a></li><li><a class="nounderline abstract_t">Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 2003; 18 Suppl 6:vi79.</a></li><li><a class="nounderline abstract_t">Meyrier A, Noël LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie. Kidney Int 1994; 45:1446.</a></li><li><a class="nounderline abstract_t">Goumenos DS, Kalliakmani P, Tsakas S, et al. Cyclosporin-A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after its administration) blood levels. Med Chem 2006; 2:391.</a></li><li><a class="nounderline abstract_t">Koike M, Honda K, Tsukada M, et al. [Low-dose cyclosporin therapy combined with prednisolone for relapsing minimal change nephrotic syndrome in adults]. Nihon Jinzo Gakkai Shi 2002; 44:447.</a></li><li><a class="nounderline abstract_t">Westhoff TH, Schmidt S, Zidek W, et al. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol 2006; 65:393.</a></li><li><a class="nounderline abstract_t">Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006; 21:1848.</a></li><li><a class="nounderline abstract_t">Li X, Li H, Chen J, et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 2008; 23:1919.</a></li><li><a class="nounderline abstract_t">Li X, Li H, Ye H, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009; 54:51.</a></li><li><a class="nounderline abstract_t">Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis 1991; 18:583.</a></li><li><a class="nounderline abstract_t">Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17:2011.</a></li><li><a class="nounderline abstract_t">Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.</a></li><li><a class="nounderline abstract_t">Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31:213.</a></li><li><a class="nounderline abstract_t">Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994; 125:981.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43:1377.</a></li><li><a class="nounderline abstract_t">Li H, Shi X, Shen H, et al. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial. Clin Ther 2012; 34:1112.</a></li><li><a class="nounderline abstract_t">Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71:1051.</a></li><li><a class="nounderline abstract_t">Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int 2018; 94:861.</a></li><li><a class="nounderline abstract_t">Jan CI, Chen A, Sun GH, et al. Recurrent minimal change disease post-allograft renal transplant. Transplant Proc 2003; 35:2888.</a></li><li><a class="nounderline abstract_t">Ponticelli C, Moroni G, Glassock RJ. De novo glomerular diseases after renal transplantation. Clin J Am Soc Nephrol 2014; 9:1479.</a></li><li><a class="nounderline abstract_t">Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.</a></li><li><a class="nounderline abstract_t">Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769.</a></li><li class="breakAll">Meyrier A. Management of idiopathic nephrotic syndrome in adults: Minimal change disease and focal segmental glomerulosclerosis. In: Evidence-Based Nephrology, Molony DA, Craig JC (Eds), Wiley-Blackwell, Oxford 2009. p.149.</li></ol></div><div id="topicVersionRevision">Topic 3045 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4162167" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term assessment of steroid therapy in childhood nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556256" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941578" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term outcome of adult-onset minimal-change nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10754411" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predictive value of repeat renal biopsies in children with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4916790" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Controlled trial of prednisone in adult patients with the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747335" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adult-onset minimal change nephrotic syndrome: a long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2042651" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877569" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3189423" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Minimal-change glomerulopathy of adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808168" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699450" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adult minimal-change disease: clinical characteristics, treatment, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205481" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23431071" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The treatment of minimal change disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275629" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3683690" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Minimal-change nephrotic syndrome in adults treated with alternate-day steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7146313" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Minimal change glomerular disease in Malaysian adults and use of alternate day steroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27807213" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385039" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15468963" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/428152" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cyclophosphamide alone in the treatment of adult patients with minimal change glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4422336" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The nephrotic syndrome in adults with 'minimal change' glomerular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4113514" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cyclophosphamide therapy in adults with minimal-change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953303" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33168602" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37180513" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989000" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10517721" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glucocorticoid-induced adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3933645" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6580858" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557879" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Short-Term Steroid Regimen for Adult Steroid-Sensitive Minimal Change Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665568" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34441929" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical Characteristics and Outcomes of Adults with Nephrotic Syndrome Due to Minimal Change Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3915841" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adult minimal change nephropathy: experience of the collaborative study of glomerular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691659" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Late recurrence of minimal lesion nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34023417" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33964312" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Minimal change disease relapse following SARS-CoV-2 mRNA vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34052236" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31575619" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Foamy Urine: Is This a Sign of Kidney Disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740915" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1860266" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554521" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25546674" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325085" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8159300" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24920841" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28979773" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688915" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21762648" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Rituximab in adult patients with immunosuppressive-dependent minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23338210" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rituximab therapy in nephrotic syndrome: implications for patients' management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34094516" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37678236" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12953048" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of idiopathic nephrosis by immunophillin modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8072258" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Sociétéde Néphrologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16848751" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cyclosporin-A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after its administration) blood levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12216477" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : [Low-dose cyclosporin therapy combined with prednisolone for relapsing minimal change nephrotic syndrome in adults].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792133" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16311257" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17911091" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406543" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951339" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401863" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849465" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mycophenolate mofetil treatment for primary glomerular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469489" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Successful mycophenolate mofetil treatment of glomerular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996374" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315953" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503105" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11374400" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29980292" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acute kidney injury complicating nephrotic syndrome of minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14697929" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Recurrent minimal change disease post-allograft renal transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700797" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : De novo glomerular diseases after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176855" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176846" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
